Inhibikase Therapeutics I... (IKT)
2.30
-0.04 (-1.71%)
At close: Feb 28, 2025, 3:59 PM
2.29
-0.43%
After-hours: Feb 28, 2025, 04:19 PM EST
No 1D chart data available
| Bid | 2.23 |
| Market Cap | 159.53M |
| Revenue (ttm) | 7.81 |
| Net Income (ttm) | -152.78M |
| EPS (ttm) | -3.12 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -11.04 |
| Analyst | Hold |
| Ask | 2.92 |
| Volume | 322,526 |
| Avg. Volume (20D) | 277,936 |
| Open | 2.46 |
| Previous Close | 2.34 |
| Day's Range | 2.25 - 2.48 |
| 52-Week Range | 1.12 - 4.20 |
| Beta | 1.06 |
About IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 8
Stock Exchange NASDAQ
Ticker Symbol IKT
Website https://www.inhibikase.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IKT stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 247.83% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 months ago
-13.14%
Inhibikase Therapeutics shares are trading lower. ...
Unlock content with
Pro Subscription
3 months ago
+3.6%
Inhibikase Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced an $8 price target.
